dehaze raises €3.2 million to build the foundational AI model for chronic disease detection, unlocking up to $800bn savings in the world’s largest healthcare cost category
Munich-based dehaze has closed a €3.2 million seed round led by YZR Capital and DN Capital, with participation from Angel Invest, ZOHO and Better Ventures.
The investment enables dehaze to meet surging international customer demand and accelerate its ambition to become the globally leading AI platform for chronic disease detection, scaling engineering, research and commercial teams and accelerating product development.
dehaze has developed a foundational AI model that significantly improves the detection of chronic diseases, enabling payers to reduce annual health spend by up to 10% [1] in a market that represents more than $8 trillion in annual spend according to the WHO [2].
dehaze is the first company to close the chronic disease detection gap. Today, physicians only have the time and tools to review less than 3% of the health data [3] theoretically available before making a decision, leading to more than 31% of chronic diseases being overlooked. dehaze surfaces these patients, enabling targeted intervention before disease occurs or worsens.
Munich– April 28th,2026 – dehaze, the Munich-based healthcare AI company, today announced the closing of a €3.2 million seed round led by YZR Capital and DN Capital, with participation from Angel Invest, ZOHO and Better Ventures.
The investment confirms dehaze’s commercial traction with international payers and its position as one of the most promising players to build the first foundational AI model for chronic disease detection. The company’s mission is to build its causal AI model that detects and explains the risks of chronic diseases so that patients can be treated sooner and more effectively, and live healthier lives.
According to WHO, chronic diseases are the single largest cost driver in every healthcare system on earth, responsible for roughly seven out of every ten deaths globally and more than $8 trillion in annual spend. Physicians have access to enormous volumes of health data, but the time and tools to review less than 3% of it before making a clinical decision. As a result, more than 31% of chronic diseases are overlooked at the point where they could still be prevented, slowed, or treated at a fraction of the later cost.
dehaze is the first company to close this gap. Its foundational model processes the full breadth of available patient data to identify individuals at elevated risk of chronic disease continuously, at population scale, and with causal explanations clinicians and payers can act on. Unlike general-purpose LLMs, which are structurally unable to draw causal conclusions from sparse and heterogeneous medical data, dehaze is built from first principles for the realities of healthcare data. The result: payers can lower medical loss ratios by up to 10%, and patients can be treated sooner and more effectively.
dehaze’s engineering, research and product teams are headquartered in Munich, with deep roots in German and European deep-tech research, supported by multiple public grants from the German Federal Ministry of Research, Technology and Space and the German Federal Ministry of Economic Affairs and Energy. Its commercial footprint is already global, with a growing pipeline of payers actively onboarding the platform, set to be enhanced by new modules focusing on recommending the next best action and full traceability. The company plans to expand the core team with medical and technical expertise to enhance the technological lead and the commercial team to meet growing commercial demand.
Marius Klages, Co-Founder and CEO of dehaze, commented:
“Chronic disease is the biggest and most expensive problem in healthcare, and it has been unsolved for one simple reason: the data exists, but no one has been able to use it. Doctors see less than 3% of what’s available before making a decision, and as a result roughly a third of chronic diseases go undetected until it’s too late or too expensive to act. That is the gap we close. We built dehaze in Munich, from first principles, as a foundational AI model for chronic disease detection - not a chatbot, not a dashboard. Our customers are global from day one, because the problem is global from day one. The speed at which payers are signing with us confirms what we believed when we started: this is a category that will be defined over the next few years, and dehaze is going to define it.”
Markus Feuerecker, Co-Founder & General Partner at YZR Capital: “At YZR Capital we focus on identifying global multi-billion USD opportunities within healthcare, that can be tackled with cutting edge AI. Oftentimes by doing that, complete value chains are innovated. With dehaze this is happening at a complete system level, finally utilizing the masses of unstructured data available in care systems for effective chronic disease prevention through causal AI. Quite naturally this is one of the most challenging tasks within health AI, therefore requiring unique teams that combine a deep technological foundation with a profound understanding of the needs of the global health insurance clients – in dehaze we found such a team. For that reason, we are particularly excited to partner with them on their mission to become the globally leading AI platform for chronic disease detection.”
Gülsah Wilke, Partner and Head of the German Office at DN Capital: “dehaze is not an LLM for medicine. Marius and the team are building the unglamorous but vitally important and scientifically rigorous layer that global healthcare has been missing; a foundation model designed for patient data, by people who understand patient data, that will shift the system from reactive to preventive. dehaze is the kind of deep-tech, mission-driven company Germany should be famous for championing.”
Press contact
Montfort Communications
Imogen Saunders, saunders@montfort.london
[1] CDC: Fast Facts: Health and Economic Costs of Chronic Conditions and EFPIA- It’s time to power up the health systems
[2] WHO: Global spending on health: Emerging from the pandemic
[3] World Economic Forum: How to harness the power of health data to improve patient outcomes
